AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
triamcinolone hexacetonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids not used as glucocorticosteroids | 4976 | 5611-51-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
synthetic glucocorticoid analog used for anti-inflammatory effects in disorders of many organ systems
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,ZAP70 | 37 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 29, 1969 | FDA | SANDOZ |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Human antichimeric antibody positive | 364.87 | 179.25 | 60 | 2532 | 1726 | 90624129 |
| Body height below normal | 346.36 | 179.25 | 59 | 2533 | 2109 | 90623746 |
| Drug specific antibody | 271.27 | 179.25 | 49 | 2543 | 2463 | 90623392 |
| Polyarthritis | 259.30 | 179.25 | 67 | 2525 | 18283 | 90607572 |
| Bone density decreased | 233.73 | 179.25 | 61 | 2531 | 17284 | 90608571 |
| Adrenal insufficiency | 226.86 | 179.25 | 67 | 2525 | 29854 | 90596001 |
| Antibody test positive | 200.18 | 179.25 | 39 | 2553 | 2950 | 90622905 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Human antichimeric antibody positive | 384.12 | 162.96 | 61 | 2595 | 1681 | 110584962 |
| Body height below normal | 358.97 | 162.96 | 59 | 2597 | 2025 | 110584618 |
| Polyarthritis | 278.77 | 162.96 | 69 | 2587 | 18894 | 110567749 |
| Drug specific antibody | 274.00 | 162.96 | 49 | 2607 | 2779 | 110583864 |
| Bone density decreased | 249.03 | 162.96 | 61 | 2595 | 15981 | 110570662 |
| Adrenal insufficiency | 215.36 | 162.96 | 67 | 2589 | 42323 | 110544320 |
| Antibody test positive | 211.58 | 162.96 | 40 | 2616 | 3080 | 110583563 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
| FDA EPC | N0000175576 | Corticosteroid |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D005938 | Glucocorticoids |
| MeSH PA | D006728 | Hormones |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:50857 | anti-allergic agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:77715 | nasal decongestant |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Lichen planus | indication | 4776004 | DOID:9201 |
| Keloid scar | indication | 33659008 | |
| Lichen simplex chronicus | indication | 53891004 | |
| Necrobiosis lipoidica diabeticorum | indication | 56391002 | |
| Alopecia areata | indication | 68225006 | DOID:986 |
| Discoid lupus erythematosus | indication | 200938002 | |
| Idiopathic thrombocytopenic purpura | contraindication | 32273002 | DOID:8924 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.08 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| I7GT1U99Y9 | UNII |
| D00985 | KEGG_DRUG |
| 4017601 | VUID |
| N0000179269 | NUI |
| 4017599 | VANDF |
| 4017601 | VANDF |
| C0077004 | UMLSCUI |
| CHEBI:9670 | CHEBI |
| CHEMBL1200878 | ChEMBL_ID |
| 21826 | PUBCHEM_CID |
| 1907 | INN_ID |
| C005900 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10759 | RXNORM |
| 354456 | MMSL |
| 4582 | MMSL |
| 5613 | MMSL |
| 5616 | MMSL |
| d00620 | MMSL |
| 002188 | NDDF |
| 002191 | NDDF |
| 116594009 | SNOMEDCT_US |
| 412524002 | SNOMEDCT_US |
| 6028009 | SNOMEDCT_US |
| C0040864 | UMLSCUI |
| DB00620 | DRUGBANK_ID |
| 31307 | PUBCHEM_CID |
| 755 | INN_ID |
| D014221 | MESH_DESCRIPTOR_UI |
| CHEBI:9667 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Hexatrione2% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59137-570 | INJECTION, SUSPENSION | 40 mg | INTRA-ARTICULAR | Unapproved drug for use in drug shortage | 3 sections |